Synthesis, anticancer activity, and β‐lactoglobulin binding interactions of multitargeted kinase inhibitor sorafenib tosylate (SORt) using spectroscopic and molecular modelling approaches. (12th August 2020)
- Record Type:
- Journal Article
- Title:
- Synthesis, anticancer activity, and β‐lactoglobulin binding interactions of multitargeted kinase inhibitor sorafenib tosylate (SORt) using spectroscopic and molecular modelling approaches. (12th August 2020)
- Main Title:
- Synthesis, anticancer activity, and β‐lactoglobulin binding interactions of multitargeted kinase inhibitor sorafenib tosylate (SORt) using spectroscopic and molecular modelling approaches
- Authors:
- Tanzadehpanah, Hamid
Bahmani, Asrin
Hosseinpour Moghadam, Neda
Gholami, Hamid
Mahaki, Hanie
Farmany, Abbas
Saidijam, Massoud - Abstract:
- Abstract: Sorafenib tosylate (SORt) is an oral multikinase inhibitor used for treatment of advanced renal cell, liver, and thyroid cancers. In this study, this drug was synthesized and its antiproliferative activities against HCT116 and CT26 cells were assessed. The interaction of SORt with β‐lactoglobulin (BLG) was studied using different fluorescence techniques, circular dichroism (CD), zeta potential measurements, and docking simulation. The results of infrared (IR), mass, H NMR, and C NMR spectra demonstrated that the drug was produced with high quality, purity, and efficiency. SORt showed potent cytotoxicity against HCT116 and CT26 cells with IC50 of 8.12 and 5.42 μM, respectively. For BLG binding of SORt, the results showed that static quenching was the cause of the high affinity drug–protein interaction. Three‐dimensional fluorescence and synchronous spectra indicated that SORt conformation was changed at different levels. CD suggested that the α‐helix content remained almost constant in the BLG–SORt complex, whereas random coil content decreased. Zeta potential values of BLG were more positive after binding with SORt, due to electrostatic interactions between BLG and SORt. Thermodynamic parameters confirmed van der Waals and hydrogen bond interactions in the complex formation. Molecular modelling predicted the presence of hydrogen bonds and electrostatic forces in the BLG–SORt system, which was consistent with the experimental results. Abstract : Sorafenib tosylateAbstract: Sorafenib tosylate (SORt) is an oral multikinase inhibitor used for treatment of advanced renal cell, liver, and thyroid cancers. In this study, this drug was synthesized and its antiproliferative activities against HCT116 and CT26 cells were assessed. The interaction of SORt with β‐lactoglobulin (BLG) was studied using different fluorescence techniques, circular dichroism (CD), zeta potential measurements, and docking simulation. The results of infrared (IR), mass, H NMR, and C NMR spectra demonstrated that the drug was produced with high quality, purity, and efficiency. SORt showed potent cytotoxicity against HCT116 and CT26 cells with IC50 of 8.12 and 5.42 μM, respectively. For BLG binding of SORt, the results showed that static quenching was the cause of the high affinity drug–protein interaction. Three‐dimensional fluorescence and synchronous spectra indicated that SORt conformation was changed at different levels. CD suggested that the α‐helix content remained almost constant in the BLG–SORt complex, whereas random coil content decreased. Zeta potential values of BLG were more positive after binding with SORt, due to electrostatic interactions between BLG and SORt. Thermodynamic parameters confirmed van der Waals and hydrogen bond interactions in the complex formation. Molecular modelling predicted the presence of hydrogen bonds and electrostatic forces in the BLG–SORt system, which was consistent with the experimental results. Abstract : Sorafenib tosylate (SORt) drug was synthesized and confirmed by IR, Mass, HNMR, and CNMR. Next, its anti‐proliferative activities against HCT116 and CT26 cells were assessed. Furthermore, the interaction of SORt with β‐lactoglobulin (BLG) was studied using different fluorescence techniques, circular dichroism (CD), zeta potential measurements, and docking docking. … (more)
- Is Part Of:
- Luminescence. Volume 36:Number 1(2021)
- Journal:
- Luminescence
- Issue:
- Volume 36:Number 1(2021)
- Issue Display:
- Volume 36, Issue 1 (2021)
- Year:
- 2021
- Volume:
- 36
- Issue:
- 1
- Issue Sort Value:
- 2021-0036-0001-0000
- Page Start:
- 117
- Page End:
- 128
- Publication Date:
- 2020-08-12
- Subjects:
- β‐lactoglobulin -- docking -- MTT assay -- multispectroscopy -- sorafenib
Luminescence -- Periodicals
Bioluminescence -- Periodicals
Chemiluminescence -- Periodicals
Luminescence -- Periodicals
535.35 - Journal URLs:
- http://onlinelibrary.wiley.com/ ↗
- DOI:
- 10.1002/bio.3929 ↗
- Languages:
- English
- ISSNs:
- 1522-7235
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 5304.782850
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 15575.xml